PVX7 vaccine for advanced cervical cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new immunotherapy vaccine called PVX7 for women with advanced cervical cancer that is caused by HPV. It aims to see if the vaccine can help prevent the cancer from coming back after standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older
- You have advanced cervical cancer (stages IB1 to IVA) that is HPV-positive
- You finished your main treatment (surgery, radiation, or chemo) within the past 12 months
- You have no signs of cancer left after treatment (based on recent scans or exams)
- You are not pregnant, breastfeeding, or planning to become pregnant during the study
- You agree to avoid close contact with young children and pregnant women for one month after the vaccine
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial aims to develop a vaccine that trains your immune system to fight HPV, the virus that causes cervical cancer. By studying your blood, researchers hope to find better ways to prevent the cancer from coming back.
This Phase 2 trial tests an immune-cell treatment (E7 TCR T cells) designed to attack cancers caused by HPV type 16. It may help people whose HPV-16+ cancer has come back or not responded to standard treatment.
This Phase 1/2 trial tests a one-time infusion of special immune T cells made to recognize your HPV16 tumor. It may help your body attack the cancer, while researchers closely monitor safety and early effectiveness.
This trial tests a new experimental drug, PRGN-2009, combined with the immunotherapy pembrolizumab (Keytruda) for people with HPV-related cervical cancer that has come back or spread. It is for those who have already tried pembrolizumab and are looking for another option.
This clinical trial tests a new combination therapy (BAT1308 plus chemotherapy, with or without Avastin) for women with advanced cervical cancer that is PD-L1-positive and has not been previously treated with systemic therapy. The goal is to see if this combination can shrink tumors or slow disease progression.
This trial tests a new vaccine called PVX4 for women with HPV16-related cervical dysplasia. It aims to see if the vaccine can help clear the high-risk HPV infection and the abnormal cells on the cervix.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.